GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharvaris NV (NAS:PHVS) » Definitions » EV-to-EBITDA

Pharvaris NV (Pharvaris NV) EV-to-EBITDA : -5.59 (As of Jun. 05, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Pharvaris NV EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Pharvaris NV's enterprise value is $501.04 Mil. Pharvaris NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $-89.59 Mil. Therefore, Pharvaris NV's EV-to-EBITDA for today is -5.59.

The historical rank and industry rank for Pharvaris NV's EV-to-EBITDA or its related term are showing as below:

PHVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.37   Med: 0   Max: 3.57
Current: -5.59

During the past 7 years, the highest EV-to-EBITDA of Pharvaris NV was 3.57. The lowest was -16.37. And the median was 0.00.

PHVS's EV-to-EBITDA is ranked worse than
100% of 451 companies
in the Biotechnology industry
Industry Median: 9.15 vs PHVS: -5.59

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-05), Pharvaris NV's stock price is $16.86. Pharvaris NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.995. Therefore, Pharvaris NV's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Pharvaris NV EV-to-EBITDA Historical Data

The historical data trend for Pharvaris NV's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharvaris NV EV-to-EBITDA Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial - - -3.94 -2.28 -9.87

Pharvaris NV Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.33 -4.84 -6.55 -9.87 -9.42

Competitive Comparison of Pharvaris NV's EV-to-EBITDA

For the Biotechnology subindustry, Pharvaris NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharvaris NV's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharvaris NV's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Pharvaris NV's EV-to-EBITDA falls into.



Pharvaris NV EV-to-EBITDA Calculation

Pharvaris NV's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=501.037/-89.589
=-5.59

Pharvaris NV's current Enterprise Value is $501.04 Mil.
Pharvaris NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-89.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharvaris NV  (NAS:PHVS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Pharvaris NV's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=16.86/-1.995
=At Loss

Pharvaris NV's share price for today is $16.86.
Pharvaris NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.995.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Pharvaris NV EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Pharvaris NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharvaris NV (Pharvaris NV) Business Description

Traded in Other Exchanges
Address
Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.